Chonbuk National University Hospital
Jeonju, South Korea
NCT Number: NCT03247140
The PK Characteristics of the Co-administration of Rosuvastatin and Telmisartan/Amlodipine and JLP-1401 in Healthy Male Volunteers Volunteers
Looking for future studies?
Notify Me19 year and older
Male
Interventional
Phase 1
Jeonju, South Korea
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Administration of JLP-1401(Telmisartan/Amlodipine/Rosuvastatin)
Administration of Temlisartan/Amlosipine(Twinsta®) and Rosuvastatin(Crestor®)
Time frame: 72hr after baseline
Area under the curve of telmisartan, amlodipine, rosuvastatin at 72 hours after baseline
Time frame: 72 after baseline
Peak concentration of telmisartan, amlodipine, rosuvastatin at 72 hours after baseline
Jeil Pharmaceutical Co., Ltd.
Industry
An Open Label, Randomized, Single-dose, 4-period Cross-over Study to Compare the Pharmacokinetics and Safety Following Administration of JLP-1401 and Coadministration of Rosuvastatin and Telmisartan/Amlodipine in Healthy Adult Volunteers
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT03707899
Hypertension With Dyslipidemia
Jeonju, South Korea
View Trial Details